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Previous studies using conventional heteroantisera and monoclonal antibodies (1, 
2)  have  characterized  the  expression  of a  common  acute  lymphoblastic leukemia 
antigen (CALLA) 1 in various hematopoietic malignancies and normal tissues, CALLA 
has  been  demonstrated  to  be  a  100,000-dahon  glycoprotein  that  is  expressed  by 
leukemic  cells  from  ~80%  of  patients  with  non-T acute  lymphoblastic leukemia 
(ALL),  10%  of patients with T-ALL, and 40%  of patients with chronic myelocytic 
leukemia (CML) in blast crisis, as well as lymphoma cells from ~40% of patients with 
T  cell  lymphoblastic lymphomas and almost all  Burkitt's lymphomas and nodular 
lymphomas (3). Within the hematopoietic system, CALLA is also detected on a small 
population  of  mononuclear cells  (1-3%)  in  either  normal  or  regenerating  bone 
marrow.  Fetal  hematopoietic organs contain a  larger proportion of CALLA+  cells 
and mononuclear cell suspensions from fetal liver and fetal bone marrow have been 
found to contain 2-10% CALLA+ cells (2-5). 
Although much is  known about the  distribution of CALLA, very little is known 
about its functional role on the cell surface or its appearance during ontogeny. Recent 
studies have demonstrated that  CALLA belongs to  a  family of  100,000-dahon cell 
surface proteins that are widely expressed by hematopoietic cells (6) and is also present 
in some nonhematopoietic tissues (7). In addition, binding of j5 monoclonal antibody 
to  cell  surface  antigen results  in  the  modulation of the  expression  of CALLA  on 
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leukemic cells and  cell lines. J5  modulation occurs in  vitro  (8)  and  in vivo  (9)  and 
results in a  reversible and specific loss and internalization of cell surface CALLA (10). 
Despite  the  analogous  modulatory  behavior  of  CALLA  and  known  membrane 
receptors for various hormones, no functional role for CALLA has yet been defined. 
Given  the  compelling  data  demonstrating  that  most  tumors  of  myeloid  and 
lymphoid systems reflect phenotypes of frozen stages of differentiation corresponding 
to  their  normal  cellular counterparts,  in  this  study  we  have  purified  normal  fetal 
hematopoietic  cells  that  express  CALLA  to  further  delineate  the  role  of this  cell 
surface glycoprotein in early lymphoid differentiation. Pure populations of CALLA+ 
cells were obtained by either immune rosetting or fluorescence-activated cell sorting, 
and  these  cells  were  subsequently  characterized  using  dual  fluorescence  labeling 
techniques  for the presence of specific cytoplasmic and surface markers.  These data 
suggest that CALLA+  cells are committed lymphoid cells that are in the early stages 
of lymphoid differentiation and that, furthermore,  normal CALLA+  cells appear to 
be the normal counterparts of CALLA+  lymphoblastic leukemia cells. 
Materials  and  Methods 
Preparation of Mononuclear Single Cell Suspensions  from Fetal Tissues.  Fetal tissue specimens were 
obtained immediately after prostaglandin- or saline- induced abortions from fetuses with no 
apparent abnormalities. The age of the fetus was determined by measurements of crown-rump 
and  foot lengths.  Procurance of all specimens was approved by the Brigham  and Women's 
Hospital Committee on the Use of Human Subjects in Research, Boston, MA. 
Fetal bone marrow was obtained from femoral bones that were removed aseptically. Single 
cell suspensions were produced by flushing the intramedullary cavities with Hanks' balanced 
saline solution (HBSS). Fetal livers were minced into 1-cm 3 pieces and passed repeatedly in and 
out of a  20-cm  ~ syringe until large clumps of cells were no longer visible. Subsequently, cells 
were passed through a cone-shaped nylon mesh to obtain single cell suspensions. 
Single cell suspensions from  both  organs  were  then  layered onto  Ficoll-Hypaque (F/H) 
density gradients and after centrifugation the resulting interface cells were washed twice and 
resuspended in supplemented minimum essential medium with 2.5% pooled human AB serum 
(SMEM +  2.5% AB). For preparation of fetal liver mononuclear cell suspensions, this step was 
repeated to maximize elimination of erythrocytes. 
Monoclonal Antibodies.  The production and reactivities of the monoclonal antibodies (MoAb) 
used in this study have been described previously. A summary of the specificity  of these reagents 
is presented in Table I. 
Preparation of Rabbit Anti-Mouse tg-coated Sheep E~throcytes (R/M-SRBC).  As described previ- 
ously (23),  New Zealand white rabbits were immunized repeatedly with a  mixture of MoAb 
including J2, J5, J13, MY7, and MYS. The immune serum was first passed through a column 
of human Ig coupled to Sepharose 4B (Pharmacia) and then through a column of mouse Ig- 
Sepharose. Purified rabbit anti-mouse Ig was eluted from the second column with 1 M glycine 
buffer, pH 2.0, extensively dialyzed against 0.9% saline solution, adjusted to a concentration of 
1 mg protein/ml, and stored at -20°C. 
Sheep erythrocytes (SRBC), washed three times in saline, were coupled with the rabbit anti- 
mouse antiserum with CrCla as follows: 0.5  ml packed SRBC were mixed with 0.5 ml rabbit 
anti-mouse antiserum and 0.5 mI saline, whereupon 0.5 mt of freshly prepared CrCla solution 
(1  mg/ml) was added dropwise under vigorous stirring. After a  6-7-min incubation at room 
temperature,  the reaction was stopped with cold phosphate-buffered saline and  the coupled 
SRBC were washed three times in saline and resuspended to a  10% solution in SMEM +  2.5% 
AB. 
Immune Rosette Depletion of Myeloid and E~ythroid Cells.  To  deplete  the  mononuclear  cell 
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TABLE  I 
Summary of Monoclonal Antibodies  Used in the Purification  and Characterization  of Fetal Hematopoietic 
Cells 
Monoclonal  Molecular 
antibody  weight*  ttematopoietic cellular reactivily  Reference 
J5/J13  100,000  Early lymphoid cells, common ALL cells,  2, 32 
blast-crisis  lymphoid  CML,  Burkitt's 
lymphoma, nodular lymphoma 
26,000  Activated T cells, some thymocytes, plate-  11 
lets, early lymphoid cells, ALL cells 
29,000  B cells, monocytes, activated T cells, early  12 
34,000  hematopoietic cells 
30,000  All B cells except for plasma cells,  B cell  13,  14 
tumors  except  for  myeloma,  some 
non-T ALL cells 
94,000  Monocytes, null cells, granulocytes, acute  15, 16 
155,000  monocytic leukemia 
55,000  Monocytes, acute monocytic leukemia  I5,  16 
160,000  Differentiated  granulocytic  and  mono-  17 
--  cytic  cells,  acute  myelocytic  leukemia 
cells 
20,000  Mature T cells  18, 19 
94,000  Activated  T  cells,  rapidly  proliferating  19, 20, 21 
cells, early erythroid cells 
45,000  Activated  T  cells,  rapidly  proliferating  19, 21 
cells, early lymphoid cells, plasma cells 
55,000  T cells, thymocytes  22 
j2 
I-2 (Ia antigen) 
BI 
Mol 
Mo2 
MY7 
MY8 
T3 
T9 (transferrin receptor) 
TIO 
T1 l  (E rosette receptor) 
* Apparent molecular weight of antigen under reducing conditions in sodium dodecyl sulfide-polyacryl- 
amide gel electrophoresis. 
and  fetal  liver were  incubated  at  4°C  for  30  min  with  a  mixture  of MoAb  including:  T9 
(dilution  1:2,000),  Mol  (1:100),  Mo2  (I:100),  MY7  (1:100),  and  MY8  (1:100).  After  three 
washes in SMEM  +  2.5% AB, the cells were resuspended to  1.0 ml and mixed with  1.0 ml of 
the  10%  R/M-SRBC  solution.  When leukocyte cell numbers exceeded  200  X  10  ~,  1  3  ml  of 
R/M-SRBC  was used_ Using this method, up to 600 X  10  ~ cells can be processed in one tube. 
After a  centrifugation at  180 g  for 5  min, the rosette mixture was resuspended with a  Pasteur 
pipette until clumps were no longer visible. The quality of the rosettes was determined under 
fluorescence microscopy in an acridine orange-stained aliquot; subsequently, the rosettes were 
layered on F/H and spun for 15 rain at 1,140 g. The resulting interface suspension (subsequently 
referred  to  as  MoAb-rosette-negative  cells)  was  harvested  and  washed,  whereas  the  pellet 
(MoAb-rosette-positive  cells)  was  recovered  after  lysis  of  SRBC  with  ammonium  chloride 
buffer. The viability in each fraction was >90% and total recovery of cells was >60%. 
Purification  of CALLA +  Cells  by  Rosette  Sedimentation.  CALLA+  cells  were  purified  by  a 
second  rosette sedimentation  after labeling of the  MoAb-rosette-negative cell  fractions with 
anti-CALLA antibodies.  Pilot experiments with CALLA+  ALL  lines  (balm-1  and  Laz  221) 
had shown that the rosetting efficiency could  be increased by adding an IgM antibody, J13, 
which is also specific for CALLA, to J5 during the antibody-labeling procedure. Consequently, 
an equal mixture of J5 and J 13 (final dilution of each,  1  : 100) was used when the MoAb-roset re- 
negative cell fraction was to be rosetted. Otherwise, the rosetting was performed as described 
above. 
Purification  of  CALLA+  Cells  by  Fluorescence-activated  Cell  Sorting.  In  some  experiments, 
CALLA+  cells were purified  from  MoAb-rosette-negative fractions by fluorescence-activated 
Greaves, M.  F.,  G.  Hariri,  R.  A.  Newman,  D.  R.  Sutherland, M.  A.  Ritter,  and J.  Ritz.  Selective 
expression of the common acute [ymphoblastic leukemia (gpl00) antigen on immature lymphoid cells and 
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cell sorting after labeling with J5 antibody and a  1:50 dilution of fluorescein-conjugated  goat 
anti-mouse antiserum (G/M-FITC; Tago Inc., Burlingame, CA) for 30 min at 4 C. After two 
washes  the cells were separated into J5+ and J5-  (CALLA+ and CALLA-) subpopulations 
using an EPICS V  (Coulter Electronics Inc., Hialeah, FL). Post-sort viability in both fractions 
was >95%, and the purity of the subsets was >97% by reanalysis on the EPICS V. 
Phenotypic Analysis of CALLA +  and CALLA-  Cell Fractions.  Dual fluorescence techniques 
were  used to obtain direct evidence for the coexpression of other antigens on the CALLA+ 
cells.  With  sorted  CALLA+  cells  that  were  labeled with J5  and  G/M-FITC, capping of 
CALLA-J5-G/M-FITC complexes  was  observed  after  an  overnight  incubation at  37°C. 
CALLA+  cells  purified by J5  rosette  sedimentation were  labeled with  G/M-FITC before 
overnight incubation to induce capping of J5-CALLA complexes. 
After overnight incubation, the CALLA+ cells were incubated with appropriate dilutions of 
a second monoclonal antibody followed by addition of rhodamine-conjugated goat anti-mouse 
antisera (G/M-TRITC, 1:40 dilution) (Sigma Chemical Co., St. Louis, MO). For detection of 
the B 1 antigen, biotin-labeled anti-B  1 (1:20) and rhodamine-conjugated avidin (1:80;  Sigma 
Chemical Co.,  St.  Louis, MO)  was used. A  minimmn of 200  cells  were counted in a  Zeiss 
fluorescence microscope (Carl Zeiss, Inc., New York)  equipped with filter combinations that 
allowed for the clear distinction between fluorescein caps (J5-CALLA) and rhodamine mem- 
brane staining (second antibodies). 
The CALLA-negative cells, which contained no interfering antibodies, were  analyzed for 
reactivity with  specific  monoclonal antibodies by  indirect immunofluorescence. Cells were 
incubated with monoclonal antibody at 4°C for  30 min, washed twice,  and then incubated 
with G/M-FITC for  30  min at 4°C.  10,000 cells were then analyzed for  each reagent on a 
fluorescence-activated cell sorter (FACS-I; B-D FACS Systems,  Mountain View, CA). Back- 
ground fluorescence was  determined by incubating identical cells  with ascites  fluid from a 
nonreactive hybridoma (J0). 
Detection of Intracellular Antigens.  The terminal transferase enzyme (TdT) was detected by a 
two-layer immunofluorescence assay on cytocentrifuged, methanol-fixed cells as described by 
Bollum (24) using a kit from Bethesda Research Laboratories (Rockville, MD). Intracytoplasmic 
/z (cyto-/t) was detected on cytocentrifuged, methanol-fixed smears using directly fluorescein- or 
rhodamine-conjugated rabbit anti-p chain antisera (kindly provided by Dr.  M.  D.  Cooper, 
University of Alabama, Birmingham, AL). Nalm- 1 cells were used as positive controls for the 
intracellular markers in the TdT assay and Raji cells in the cyto-# assay. 
Modulation In  Vitro of the CALLA+  Cells.  Antigenic modulation in vitro was  induced in 
MoAb-rosette-negative cell  fractions by  addition of monoclonal antibody and  subsequent 
incubation for different periods of time at 37°C. Either J5 antibody, J0, or anti-Ia was added 
to identical cultures. To ensure antibody excess, 0.1  mg antibody per l0  s cells was used.  Cell 
culture media consisted of RPMI 1640 supplemented with  10% fetal calf serum (FCS).  After 
incubation, cells were washed twice and phenotyped as described above for the CALLA- cells. 
Myeloid Precursor Cell (CFU-G/M) Assays.  CFU-G/M were assayed as described by Griffin 
et  al.  (23) by  plating  l0  s  mononuclear cells/ml  in  Iscove's modified  Dulbecco's minimal 
essential medium containing 20% FCS and 0.3% agar (Agar Noble; Difco,  Detroit, MI), over 
a feeder layer of 1 ×  106 peripheral blood leukocytes/ml in 0.5% agar. After 10 d of culture at 
37°C in an atmosphere of 5% CO2  in humidified air, colonies (>40 cells)  were enumerated 
using an inverted microscope. 
Results 
Purification  of CALLA +  Cells from Fetal Tissues.  As shown in Fig.  1 A, mononuclear 
cells  obtained  from  fetal  bone  marrow  after  F/H  density gradient sedimentation 
primarily consisted of maturing myeloid cells. In contrast, mononuclear  cells obtained 
from  fetal  liver  (Fig.  1 E)  after  two  F/H-purification steps  consisted  primarily of 
maturing erythroid precursors. However, in both cases these cells could be removed 
from  the  mononuclear cell suspensions by rosette sedimentation with  a  mixture of 
MoAb (Fig.  1 B and F). In contrast to the MoAb-rosette-positive fractions, the MoAb- 118  CHARACTERIZATION OF  FETAL  HEMATOPOIETIC  CELLS  EXPRESSING  CALLA HOKLAND  ET  AL.  119 
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rosette-negative  suspensions  from  both  bone  marrow  (Fig.  1 C)  and  liver  (Fig,  1 G) 
were remarkably similar, consisting of a mixture of  small to medium-sized lymphocytes 
and large blast cells. When separating the MoAb-rosette-negative fraction further into 
CALLA+  and  CALLA-  subsets,  the  large blast  cells were  found exclusively  in  the 
CALLA-  fraction  (Fig.  1 D),  whereas  the  CALLA+  fraction  consisted  solely  of 
lymphoid-appearing cells  (Fig.  1 H). 
After rosette depletion of mature myeloid cells, 40-90% of the cells in MoAb-rosette- 
negative bone marrow suspensions were CALLA+. Further purification of CALLA+ 
cells was then accomplished by fluorescence-activated cell sorting using an EPICS V. 
A  representative  purification  experiment  is shown in  Fig.  2 where the percentage of 
CALLA+ cells in the MoAb-rosette-negative subset was 85%; subsequent purification 
yieIded a  population that was 98% CALLA+. 
To purify CALLA+ cells  from fetal  liver,  an  alternative  method  that  was able to 
process larger numbers of cells was used.  After two F/H  sedimentations  and  rosette 
depletion  of mature  cells with  a  mixture  of MoAb, the MoAb-rosette-negative  fetal 
liver  suspensions  contained  20-60%  CALLA+  cells.  Subsequently,  CALLA+  cells 
were purified  from the MoAb-rosette-negative fraction by indirect  immune rosetting 
with  both J5  and J13  antibodies.  Table  II  presents  the  results  of a  representative 
experiment  in  which  the  CALLA+  fetal  liver  cells  from  a  22-wk-old  fetus  were 
purified by two consecutive rosette sedimentations.  In the depletion step with MoAb- 
rosettes directed against a  mixture of erythroid and myeloid differentiation  antigens, 
>90% of the cells were removed. Of the remaining cells, approximately one-half were 
CALLA+,  and  after  labeling  these  MoAb-rosette-negative  cells  with  J5  and  J13 
antibodies,  they  could  be  separated  into  CALLA+  and  CALLA-  fractions  by  a 
second rosetting with  R/M-SRBC.  The yields in  each of the rosette  sedimentations 
ranged from 45 to 70%. 
Surface Antigens Expressed by CALLA +  and CALLA-  Cells.  The persistance of  J5-G/ 
M-FITC complexes as caps on sorted  and  rosetted  CALLA+ cells  (after addition  of 
FIc.  2.  Isolation of CALLA+  cells by cell sorting on an  EPICS V cell sorter. X-axis, relative 
fluorescence intensity. Y-axis, cell number  (10,000 cells analyzed per panel). Z-axis, light scatter 
(relative cell size). A, MoAb-rosette negative BM cells labeled with G/M-FITC. B, same cells as in 
A labeled with J5. C, reanalysis of sorted JS+ cells. HOKLAND  ET  AL.  121 
TABLE  II 
Purification of CALLA +  Gel#from Fetal Liver by Immune Rosette 
Sedimentations 
Total J5+  Percent J5+  Cell fraction  Total cells  cells  ceils* 
×  10  °  ×  lOa 
Unseparated~:  510  35.7  7 
MoAb-rosette positive§  320  6.4  2 
MoAb-rosette negative§  38  20.1  53 
MoAb-rosette negative, J5-[I  l 2  0.4  3 
MoAb-rosette negative, Js+ll  11  10.5  >95 
* Determined by indirect immunofluorescence assay and FAGS analysis. 
:~ Mononuclear cell  suspensions purified two times by F/H  density-gradient 
sedimentation. 
§ Cells obtained from interfaces (rosette negative) or pellets (rosette positive) 
after R/M-SRBC immune rosette sedimentation with cells labeled simulta- 
neously with Mol, Mo2, MY7, MY8, and T9 monoclonal antibodies. 
[I Rosette-negative cell suspensions obtained after depletion with Mol, Mo2, 
MY7, MY8, and T9 monoclonal antibodies and R/M-SRBC were incubated 
with J5 antibody and  R/M-SRBC.  J5-  (interface cells)  and J5+  (pellet 
ceils)  populations  were  then separated  by  an  additional  immune rosette 
sedimentation. 
TABLE  III 
Phenotypic Analysis  of CALLA +  Cells from Fetal Hematopoietic Tissues with Monoclonal Antibodies 
Percent positive cells* 
Cell source  Age  MY7/  T3/ 
J2  J5  j13  Ia  TI0  BI~:  MY8§  T9  Tll§ 
Bone marrow 
Liver 
wk 
2211  >95  >95  NT**  >95  >95  45  NT  NT  NT 
2211  >95  >95  >95  >95  >95  41  <5  NT  NT 
2311  NT  >95  NT  >95  >95  52  NT  NT  NT 
21 ¶  >95  >90  >95  >95  >95  31  <5  <5  <5 
2211  >95  >95  >95  >95  >95  39  <5  <5  <5 
23¶  >95  >95  >95  >95  >95  30  <5  <5  <5 
24¶  NT  >90  NT  >95  >95  27  NT  NT  NT 
* Determined by fluorescence microscopy of J5+ cells incubated overnight at 37°C with G/M-FITC to 
obtain capping and subsequently stained with a second monoclonal antibody and G/M-TRITC. 
:~ Labeled with biotin-conjugated B 1 followed  by rhodamine-labeled avidin. 
§ Labeled simultaneously with both monoclonal antibodies noted. 
11 Purified from MoAb-rosette-negative cell fractions by cell sorting. 
¶ Purified from MoAb-rosette-negative ceil fractions by J5 rosette sedimentation. 
** Not tested. 
G/M-FITC  to  the latter)  allowed  for the definition  of other cell surface  antigens  on 
these cells  by a  second  monoclonal  antibody  and  G/M-TRITC.  The  results  from  a 
series of experiments  with both  fetal bone marrow  and  fetal liver of different ages are 
given in Table  III.  Although  these cells have  been  isolated  from  different  tissues by 
two different methods,  the cells displayed similar cell surface antigens. The  purity of 
each suspension,  as judged  by the presence of J5-FITC  caps,  exceeded  90%  in every 
instance. It should also be noted that addition  of more J5 antibody  and G/M-TRITC 122  CHARACTERIZATION OF FETAL ItEMATOPOIETIC CELLS  EXPRESSING  CALI,A 
did not give any additional fluorescence, indicating that all of the J5 surface antigen 
was located within the G/M-FITC  cap and that these cells had not synthesized more 
CALLA during the overnight culture.  Further analysis with J13  antibody, which  is 
also specific for CALLA, showed  that  nearly all the cells bound J13  within  the J5- 
FITC  caps.  There  was  also  no  appreciable cell surface  staining with J13  antibody 
other than that found in the J5 caps. 
Three antigens, Ia, J2, and T10, were found on virtually all the CALLA+  cells. In 
contrast  to  the  reactivity  pattern  seen  with  J13,  these  antigens  were  uniformly 
distributed along the cell membrane and were distinct from CALLA. The B 1 antigen, 
in contrast, was only found on a  fraction of the CALLA+  cells, and,  when  present, 
was uniformly distributed on the cell surface. Very few CALLA+  cells were reactive 
with  anti-myeloid  or  T  cell  antibodies.  Thus,  virtually  all  CALLA+  fetal  bone 
marrow and liver cells were J2+,  Ia+, T10+,  MY7/8-,  T3/9/11-,  whereas 30-50% 
expressed B 1. 
The phenotype of the CALLA-  cells obtained after J5/J13  rosette sedimentation 
of MoAb-rosette-negative fractions was  determined by indirect immunofluorescence 
with subsequent  analysis on  a  FACS-I. As shown  in Table IV, these cells have been 
effectively depleted of CALLA+  cells, as judged by the low numbers of cells reactive 
with  the J5  and J13  antibodies. Likewise, very few  myeloid or mature T  cells were 
found.  On  the  other  hand,  significant  percentages  of these  cells expressed Tl0.  In 
contrast to the analysis of CALLA+  cells, only a  minority of the CALLA-  cells were 
reactive with either J2 or anti-B1. 
The CALLA+  and  CALLA-  populations were  also analyzed for the presence of 
nuclear TdT and cyto-~ after methanol fixation. As shown in Table V,  10-30°7c of the 
CALLA+  cells express cyto-/t chains, but this marker is not restricted to the CALLA+ 
subset because 10-15% of CALLA-  cells also contain cyto-/*. Furthermore, the finding 
of cyto-/~+ cells within  the CALLA-  subset  correlates rather closely with  the den> 
onstration of 11-17%  B 1+ cells within this population  (Table IV). When expression 
of TdT was examined, it was found that 5-25% of CALLA+  cells exhibited a  nuclear 
TdT  staining pattern. In the CALLA-  population, a  somewhat  higher percentage of 
cells  (35-50%)  was  TdT  positive.  In  further  experiments,  biotin-labeled  B1  and 
rhodamine-avidin were combined with  the  intracellular markers in  CALLA+  cells. 
As summarized in Table VI, it was determined that  nearly all of the B 1+ cells were 
TABLE  IV 
Phenotypic Analysis  of MoAb-Rosette-negative,  CALLA-  Cells" Isolated from Fetal Liver 
Percent positive cells* 
Age of 
MY7/  fetus  J2  J5  J13  Ia  T10  BI  MY8$  T9  T3/Tll} 
wk 
22  23  3  5  56  74  13  <1  0  2 
22  16  <1  6  47  57  11  <1  4  <1 
23  33  2  2  63  49  17  6  NT§  6 
27  13  3  2  NT  54  16  5  NT  NT 
* Determined by indirect immunofluorescence assay and FACS analysis. 
Labeled simultaneously with both monoclonal antibodies noted. 
§ Not tested. HOKLAND  ET  AL. 
TABLE  V 
Intracellular Markers of Purified CALLA +  and CALLA- Fetal Cells 
123 
Cell  source  Age  CALLA  Cyto-/.t*  TdT* 
wk 
Bone marrow  22  +:]:  17  7 
Bone marrow  23  +  23  16 
Liver  21  +  14  7 
Liver  22  +  27  19 
Liver  23  +  21  21 
Liver  22  -§  12  43 
Liver  23  -  10  39 
Liver  27  -  15  47 
* Percent  positive cells  determined  by immunofluorescence microscopy. 200 
cells were scored in each experiment. 
:1: +, MoAb-rosette negative, CALLA+. 
§ -, MoAb-rosette negative, CALLA-. 
TABLE  VI 
Double Marker Analysis of CALLA +  Cells with B1 Antibody and lntracellular 
Antigens 
Subset  Tissue  Age  TdT+  TdT-  Cyto-~+  Cyto-#- 
wk 
B 1 positive  Bone marrow  23  6  94*  44  56 
Liver  23  13  87  28  72 
B1 negative  Bone marrow  23  28  72  2  98 
Liver  23  32  68  1  99 
* At least 200 cells were scored by fluorescence microscopy and the percentage of cells 
positive and negative for a specific  marker was subsequently calculated. 
A. Control Modulolion 
z 
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FIG.  3.  Modulation of CALLA in vitro. MoAb-rosette-negative BM suspensions were incubated 
at  37°C for 24  h  with ascites from the nonreactive clone J0  (A), with J5  (B), or with the anti-Ia 
antibody 12  (C).  Subsequently, cells were labeled with either J5 or I2, followed by G/M-FITC, or 
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TABLE  VII 
Effect of CALLA Modulation by J5 Anttbody In  Vitro on Expression of Unrelated 
Surface Antzgens 
Incubation 
with J5 
Percentage posilive cells* 
J2  J5  J13  T10  B1  Ia 
h 
0  NT$  64  NT  NT  19  82 
24  87  6  4  91  21  92 
48  81  2  4  95  19  96 
* Determined by indirect irnmunofluorescence  assay and FACS analysis. 
:~ Not tested. 
TABLE  VIII 
Analysis of CFU-G/M Cells 
Colonies/105  Percent 
Specimen  Subset *  cells:l:  yield§ 
Liver  Unseparated cells  980  -- 
MoAb-rosette negative, CALLA-  1,600  56.0 
MoAb-rosette negative,  CALLA+  50  0.4 
Bone marrow 
Liver 
Unseparated cells  220  -- 
MoAb-rosette positive  70  18.5 
MoAb-rosette negative  720  78.5 
MoAb-rosette negative, CALLA-  2,100  76.3 
MoAb-rosette negative, CALLA+  50  0.1 
Unseparated cells  650  -- 
MoAb-rosette positive  53  5.8 
MoAb-roset te negative  1,600  45.7 
MoAb-rosette negative, CALLA+  16  0.0 
* For explanation, see legend  to Table II. 
~: Scored day tO. 
§ Based on the number of colonies compared with unseparated cells. 
found  in  the TdT-  subset  and  that  the cyto-/x+ cells were a  subset  of the B 1  +  cells. 
This  suggests  that  there  is  very little overlap between  subsets  expressing  either TdT 
or cyto-# within CALLA+  fetal cells. 
Modulation of CALLA Expression.  Previous studies using leukemic cells and cell lines 
have demonstrated  that  binding  of J5  monoclonal  antibody  to  cell surface  CALLA 
results  in  the  specific  modulation  of  this  cell  surface  antigen.  We  were  therefore 
interested  in  evaluating  the  relevance  of  this  phenomenon  using  nonmalignant 
CALLA+  ceils.  MoAb-rosette-negative  bone  marrow  (BM)  suspensions  highly  en- 
riched  for CALLA+  cells were  incubated  for  various  periods  of time with  either J0 
(ascites  from  a  nonreactive  hybridoma),  J5,  or  anti-Ia,  which  has  previously  been 
shown  not  to  modulate  Ia antigen  expression  (8).  As can  be seen  in  Fig.  3 A, 65%  of 
the  unmodulated  cells  were  CALLA+  and  85%  bore  Ia  antigens.  After  incubation 
with J5 at 37°C, 80% of the CALLA+  cells no longer expressed either surface antigen 
or J5 antibody.  However, these cells continued  to express  Ia antigen.  In contrast,  the 
Ia  antibodies  did  not  affect  the  expression  of Ia  antigen  (Fig.  3C).  Using  a  larger HOKLAND  ET  AL.  125 
panel of MoAb to analyze the J5-modulated cells (Table VII), it was seen that  the 
decrease in J5 reactivity was accompanied by a similar decrease in J13 expression. In 
contrast, only minor changes were seen in the expression of the non-CALLA-related 
antigens B1, J2, T10, and Ia even when the incubation period was extended to 48 h. 
CFU-G/M Assays.  Previous studies using adult bone marrow or peripheral blood 
depleted of CALLA+ cells by J5 and complement  (C)  treatment have shown  that 
such  procedures did  not  selectively deplete  this  population  of committed myeloid 
precursor cells (GFU-C, BFU-E, CFU-E, CFU-G/E)  (25). In Table VIII, data from 
experiments where different purified fractions of fetal liver and  fetal bone marrow 
were  tested  for activity  in  CFU-G/M  assays  are  shown.  Irrespective of the  tissue 
source and the method of purification, the CALLA+ cell fractions contained virtually 
no  CFU-G/M.  In  contrast,  most  of the  CFU-G/M  could  be  recovered from  the 
MoAb-rosette-negative and the CALLA- fractions. Since none of the antibodies used 
during the rosette depletion reacted with CFU-G/M, the low number of colonies in 
the MoAb-rosette positive fractions strongly indicate that  very little nonspecific loss 
of CFU-G/M occurred during rosette depletion. 
Discussion 
The  series  of experiments  described  in  this  study  was  designed  to  purify  and 
characterize normal hematopoietic cells that express CALLA from fetal liver and fetal 
bone marrow, where they represent a relatively small fraction of the total rnononuclear 
cell population. A major reason for the success of the purification procedure was the 
initial MoAb-rosette depletion step, where R/M-SRBG were used to rosette leukocytes 
labeled  with  a  mixture  of MoAb  against  erythroid  and  myeloid  differentiation 
antigens.  In  the subsequent  rosette sedimentation,  large numbers  of erythroid and 
myeloid cells could be removed quickly and effectively. In this context, T9 antibody, 
which  defines  the  transferrin  receptor  (20)  was  particularly  helpful,  because  the 
majority of mononuclear cells in fetal liver suspensions, even after two F/H centrifu- 
gations, were normoblasts.  In  fetal bone marrow,  the resulting rosette-negative cell 
suspensions were so enriched for CALLA+ cells that frequently these cells were >80% 
pure. Subsequently, further purification of CALLA+ cells was obtained either by cell 
sorting or by additional immune rosetting with J5 and J13 antibodies. 
After purification,  CALLA+  cells  from  both  fetal  liver and  fetal  bone  marrow 
appeared to be a  homogeneous population of medium-sized lymphocytes. However, 
with a series of monoclonal antibodies and immunofluorescence assays for intracyto- 
plasmic-/~  and  TdT,  we  have  been  able  to  demonstrate  that  the  phenotype  of 
CALLA+ cells is strikingly heterogeneous. This was found particularly when markers 
for immature B cells were used, because only ~40% of the cells were positive for the 
B1 differentiation antigen and  15-30% expressed cyto-# (Tables III and V). Further- 
more, only a  minority (5-25%)  of the CALLA+ cells contained TdT (Table V). In 
contrast, virtually all CALLA+ cells expressed Ia, T10, and J2 antigens,  and  there 
were  no  major  differences  between  cells  isolated  from  fetal  liver  and  fetal  bone 
marrow. It should be noted, however, that some CALLA+ cells were also lost at each 
step of the purification procedure. For example, as shown  in Table II, the MoAb- 
rosette-positive population contained 2% J5+  cells, and  the MoAb-rosette-negative, 
J5-rosette-negative  population  contained  3%  J5+  cells.  As  these  CALLA+  cells 
comprised  very small  fractions of these  populations,  they could not  be accurately 126  CHARACTERIZATION OF FETAL  HEMATOPOIETIC CELLS  EXPRESSING  CALLA 
characterized.  However,  because  these  losses  appeared  to  be  nonspecific,  we  have 
assumed  that  the  J5+  cells  that  were  enriched  and  purified  at  each  step  are 
representative of the entire CALLA-positive population. 
Earlier studies have demonstrated  that  leukemic cells from ~50% of patients with 
non-T ALL were reactive with B1 antibody (14). When expression of B1 antigen was 
correlated with expression of CALLA, it was found that expression of B 1 was restricted 
to those  tumor cells  that  were also  CALLA+. Furthermore,  recent  studies  using  in 
vitro  differentiation  of ALL cells  by phorbol  diester  showed  that  ALL cells  which 
were  CALLA+,  B1-  could  be  induced  to  express  B1  surface  antigen,  whereas 
CALLA-  ALL cells  could  not  be  induced  to express  B1  (26).  Taken  together,  this 
analysis of leukemic cells suggested  that  the majority of CALLA+  non-T ALL cells 
were  derived  from the  B  cell  lineage  and  Ied  us  to predict  that  CALLA would  be 
expressed at an earlier point in B cell development than B t. The analysis of CALLA+ 
fetal  hematopoietic  cells  indicates  that  a  large  fraction  of these  cells  are  indeed  in 
early phases of B cell development.  In fact, the phenotype of normal CALLA+ cells 
is  almost  identical  to  that  of CALLA+  leukemic  cells,  and,  as  has  been  suggested 
previously (4, 5), these normal cells appear to be the normal counterpart of ALL cells. 
One major difference, however, is that only a small fraction of normal CALLA+ fetal 
lymphoid cells are TdT+,  whereas almost all ALL cells contain this nuclear enzyme. 
In  addition  to  allowing  a  direct  comparison  of the  surface  markers  of normal 
CALLA+  cells  with  leukemic  cells,  our  purification  of CALLA+  and  CALLA- 
populations has allowed the identification of fetal lymphoid cells at different stages of 
maturation.  It is evident  that within the CALLA+ positive population at least  three 
subsets  can  be  identified.  The  first,  and  most  differentiated,  subset  expresses  both 
surface B 1 and cyto-bt  , and therefore corresponds to a  population that has previously 
been classified as "pre-B" cells (27, 28). In addition, these cells express Ia, J2, and T10 
antigens  (as  do all  CALLA+  cells),  but  few of these cells  appear  to be TdT+.  The 
second, less mature, subset  has an identical surface phenotype (CALLA+, Ia+, J2+, 
T10+, BI+) but does not express cyto-~ or TdT. These cells appear to be at an earlier 
stage  of lymphoid differentiation,  but  the  expression  of B1  suggests  that  they have 
already been committed to the B cell lineage.  In studies noted previously (26), ALL 
cells with this phenotype can be induced to express cyto-/~ with phorbol diester.  The 
third subset of CALLA+ cells expresses Ia, J2, and T 10 but does not express B 1. The 
lineage  of these  cells  is  not  clearly  established  by  their  surface  phenotype  because 
none of these  antigens  are  lineage  specific.  Although  a  significant  fraction  of these 
cells is TdT+,  most are TdT-.  It is likely that some cells within  this group are very 
early B cells that will subsequently express B 1 and then cyto-~ with further differen- 
tiation.  However, the expression of CALLA is not restricted to B cells or B cell tumors 
because some T  cell malignancies (T-ALL and lymphoblastic lymphoma) also express 
this antigen.  It is  therefore  possible  that  some ceils within  this  group may be T  cell 
precursors, with yet-undefined surface markers, that will later migrate to the thymus 
where further differentiation will occur. 
Within the CALLA-  cell fraction that was first  depleted of mature erythroid and 
myeloid cells by immune rosetting and then further purified by removal of CALLA+ 
cells,  our  results  also  indicate  considerable  heterogeneity.  Firstly,  Giemsa-stained 
smears demonstrated that this fraction consisted of both large blast cells and small- to 
medium-sized  lymphocytes (Fig.  1).  Approximately  60% were T10+,  55% were Ia+, HOKLAND ET AL.  127 
20% were J2+, and  15% were B 1  +  (Table IV). In addition, 35-50% of the CALLA- 
cells  were  TdT+.  It  therefore  seems  likely  that  this  fraction  contains  very  early 
lymphoid precursor cells in addition to almost all myeloid precursor cells (here, CFU- 
G/M). Phenotypically, these cells appear to represent the nonmalignant counterparts 
of undifferentiated CALLA-- ALL cells. The heterogeneity of the CALLA-  fraction 
is further emphasized by the small but significant  number of BI+ cells within  this 
population.  Because we did  not  test  for expression of surface Ig, it  is  possible that 
some of these CALLA-, B 1  +  cells are mature B cells. However, a small but significant 
percentage of CALLA- cells also express cyto-#, and it is therefore evident that not 
all pre-B are contained within the CALLA+ population.  Recent clinical studies also 
support  the  conclusion  that  the  most  immature  stem  cells  (both  myeloid  and 
lymphoid)  do not express CALLA. In these studies, patients with CALLA+ ALL in 
second remission received ablative chemotherapy and total body irradiation followed 
by infusion  of autologous  bone marrow that  had  been  depleted  of CALLA+  cells 
(both normal and leukemic) by in vitro treatment with J5 antibody and C (29). All 
patients thus far have been engrafted with antibody-treated bone marrow, and two 
patients who have been followed for >1 yr have demonstrated complete reconstitution 
of all myeloid and lymphoid populations. 
Earlier studies  using CALLA+  leukemia cells and  cell  lines  have shown  that J5 
antibody induces antigenic modulation of cell surface antigen  (8). This phenomenon 
has  had  important  implications  for  the  passive serotherapy  of patients  with  ALL 
because J5 antibody infusions lead to loss  of CALLA expression on malignant cells 
without  impeding  their  growth  (9).  The  data  presented  in  Fig.  3  and  Table VII 
demonstrate that modulation of CALLA by J5 antibody is a physiologic phenomenon 
that  occurs on  normal  CALLA+  ceils as  well.  Thus,  whereas  CALLA modulation 
may  be  a  mechanism  whereby  leukemic  cells  may  become  resistant  to  antibody- 
mediated lysis, the modulation of CALLA on fetal cells may be indicative of a normal 
functional  property of this  cell  surface  glycoprotein.  Other  surface  molecules  that 
undergo  antigenic  modulation  such  as  surface  Ig  (30),  C3b  receptor  (31);  and  T3 
antigen  (32)  appear  to  have  specific  membrane  receptor-like  functions;  CALLA 
modulation may therefore be analogous to the phenomenon of "down-regulation" in 
which expression of cell surface receptor is decreased in the presence of excess ligand 
or hormone (33,  34). 
Summary 
Fetal hematopoietic cells that express the common acute lymphoblastic leukemia 
antigen  (CALLA)  were  purified  from  both  fetal liver and  fetal  bone  marrow  by 
immune rosetting with  sheep erythrocytes coated with  rabbit anti-mouse immuno- 
globulin  and  by  fluorescence-activated  cell  sorting.  Dual  fluorescence  techniques 
disclosed that these cells were heterogenous with respect to the expression of a series 
of differentiation  and  activation  antigens  defined  by monoclonal antibodies.  Thus, 
whereas all CALLA+ cells were Ia+ and expressed two activation antigens, J2 and 
T10, only 30-50% expressed B 1 antigen.  Furthermore, using methanol-fixed cells, it 
could  be shown  that  ~20%  contained  intracytoplasmic ~  chains  (cyto-/l)  and  that 
15% were positive for the terminal transferase enzyme (TdT) marker. The CALLA+ 
fetal cells thus closely resemble the childhood acute lymphoblastic leukemia cell with 
respect to surface marker phenotype. A population of CALLA-- cells devoid of mature 
erythroid and myeloid surface markers was found to contain higher numbers of TdT+ 
cells but  lower numbers of cyto-#, B1,  and  Ia+ cells than  the CALLA+  subset.  In 128  CHARACTERIZATION OF FETAL HEMATOPOIETIC  CELLS  EXPRESSING  CALLA 
vitro  analysis of normal,  purified  CALLA+  cells demonstrated  that  incubation  at 
37°C  with  J5  monoclonal  antibody  specific  for  CALLA  resulted  in  the  specific 
modulation  of surface  antigen.  Similar results  have  previously been  obtained  with 
CALLA+  tumor cells. Although phenotypic analysis of CALLA+  cells suggests that 
these cells are relatively immature  lymphoid cells, CALLA+  cells do not  appear to 
contain either myeloid precursor cells (CFU-G/M) or the earliest lymphoid stem cells. 
We  thank  Lori  Palley for  technical assistance and  Pearl  Leavitt for  help  in  preparing the 
photomicrographs. 
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